Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates Ne...( HILTON HEAD ISLAND S.C. Sept. 9 /...),Health

HILTON HEAD ISLAND, S.C., Sept. 9 /PRNewswire/ -- At approximately 3:21 PM today, Dr. Roger Kenneth Hershline PhD MD, Chairman and Founder of CureHIV.us, agreed to act as a conduit to provide samples of Global Humanceuticals, Inc's., new extremely effective, safe and stable drug candidate to profit, non-profit, academic, government, non-government, U.S. and foreign institutions, organizations, and corporations, under mutual agreements, contracts or partnerships, to spur theoretical, objective, mechanistic, developmental or clinical research. This unique new chemical entity is referred to as compound NIAID #11039. However, this invention has already received a patent called: Antiviral Composition, U.S. patent number: 6,821,958 on November 23, 2004. The World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

"This gift is intended to extend technology that no one else posses on this planet." Stated Dr. Hershline. "Already, Chinese scientists are very interested." Dr. Hershline hosted Session V at the World Aids Day Conference China Dec 1 to Dec 3, 2006, to initially present data an NIAID #11039. There was, unfortunately, a communication error from the National Institute of Health (NIH of the United States) to Dr. Hershline, which prevented presentation of test results.

The compound has a non-toxic alpha-glucose backbone, obtained from an abundant natural source. The backbone is chemically bi-substituted in a random fashion, by a new reaction. "The substitution groups are different sulfur based viral de-activating groups that work together to provide viral entry inhibition at concentrations of one pico-Molar. This active concentration is equivalent to diluting a 1% solution one million times.

The random substitutions are intended to prevent the virus from escaping de-activation thru mutation. "Global Humanceuticals, Inc.'s NIAID #11039 is the first drug designed to prevent
'/>"/>